Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
ROSSARI
Mr. Sunil Srinivasan Chari · Mumbai, India · 585 employees
₹506.00
▲+0.34%Rossari Biotech, a specialty chemicals player, is witnessing strong earnings growth and is priced attractively, warranting a strong buying opportunity.
Exchange
NSI
Currency
INR
Day range
₹502.95 – ₹517.60
52-week range
₹375.00 – ₹713.60
Sector
Basic Materials
Industry
Specialty Chemicals
AI investment rating
AI analysis80% confidence
Trading in the upper third of its 1-year range at ~ 506 INR, Rossari Biotech appears somewhat undervalued compared to its peers and growth prospects.
29.1% below the 1-year high · trend down
Hedge-fund memo
Today
Rossari Biotech is trading 0.34% higher on a relatively stable day, with a volume of 36,814 shares.
This week
The stock has been trending higher, with a 52-week high of 713.6 INR.
This month
Rossari Biotech has been among the top performers in its sector over the past month.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
8 headlines · 5 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 3 recent quarters (EPS actual vs. consensus).
6.33 vs 8.8
-28.07% surprise
8.29 vs 6.3
31.59% surprise
6.65 vs 6.4
3.91% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| ROSSARI | 28.03B | 18.62 | — | 7.89% | 28.20% |
| LXCHEM | 55.58B | 70.11 | 4.08% | 7.09% | 3.60% |
| FINEORG | 146.98B | 35.26 | 16.82% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High debt levels
Mitigation: Strong revenue growth and increasing profitability could help the company manage its debt burden.
Dependence on a few major customers
Mitigation: Diversifying the customer base and expanding product offerings could mitigate this risk.
Business intelligence
Competitive moat
Rossari Biotech's diversified product portfolio and strong relationships with customers provide a durable competitive advantage in the specialty chemicals sector.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Increasing demand for specialty chemicals and expanding product offerings
Thesis builder
Bull case
The company is poised for strong growth due to increasing demand for specialty chemicals and expanding product offerings.
Base case
Rossari Biotech's diversified product portfolio and strong relationships with customers provide a solid foundation for growth.
Bear case
High debt levels and dependence on a few major customers pose risks to the company's financial health and growth prospects.
Time horizon
In the short to medium term, we expect Rossari Biotech to maintain its growth momentum, driven by increasing demand for specialty chemicals.
Est. CAGR
10-20%
Entry (qual.)
Investors can consider initiating a position in Rossari Biotech at current levels, given its attractive valuation and growth prospects.
Exit (qual.)
Investors may consider reducing their exposure as the stock approaches its 52-week high or if there are signs of slowing growth.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how ROSSARI fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain ROSSARI for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Investors should continue to monitor the stock's performance and adjust their investment strategies accordingly.
Moneycontrol.com·8h ago·large multi-year AI deal
Dailyhunt·17h ago·no specific company mention
MarketsMojo·19h ago·sell rating assigned
CXO Digitalpulse·1d ago·no specific company mention
MarketsMojo·1d ago·stock outperforms sector
Whalesbook·5d ago·revenue surge but decreased margins
Whalesbook·5d ago·revenue surge but decreased profit
Whalesbook·5d ago·revenue surge but decreased profit
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 18.07% |
| 2.40% |
| ROUTE | 34.56B | 13.92 | — | 7.05% | 9.60% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹502.95
Resistance (day/52w high)
₹517.60
Volume
36,814
Trend
down
RSI (14)
45
MACD
bearish
MA cross
death
50-day MA
₹522.87
200-day MA
₹533.87
vs 200-DMA
-5.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 80%